Immunis Announces Preliminary Results from First-Ever Phase 2 Study of a Secretome-Based Biologic Showing Weight Loss with Preserved Muscle and Improved Gait Speed in Obese Sarcopenic Seniors
Immunis, a clinical-stage biotech company pioneering multi-active secretome-based biologics, today announced positive topline interim results from STEM-META, a double-blind placebo-controlled study of the IMM01-STEM secretome in overweight seniors experiencing muscle loss and metabolic dysfunction. In recognition of the news, Immunis Chairman, Dr. Hans Keirstead, will be speaking at Biotech Showcase on a panel about cutting-edge immune-based therapeutics.
